Ian is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto and San Diego offices. +/-

He assists private and public companies in creating and implementing strategies to optimize their technology and other assets, advising them on a variety of legal and business issues.

Ian represents clients in domestic and international transactions involving intellectual property or product rights, including collaboration, development, manufacture, supply and distribution agreements, technology acquisitions, university licenses and the formation of joint ventures and other types of strategic alliances. Ian has a wide variety of business and legal experience covering a full range of issues and transactions facing technology companies, particularly in the biopharmaceutical and life sciences industries. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

Prior to rejoining the firm in 2002, Ian was senior vice president of corporate and business development at Third Wave Technologies, Inc., where he was responsible for implementing and managing its product development and licensing strategies for both research and clinical markets. Additionally, he played a significant role in Third Wave's financing strategy (including its February 2001 IPO) and developing and maintaining significant customer and collaborator relationships. Because of Ian's company-based experience, he is particularly attuned to issues faced by emerging company clients.

Matt is a trademarks and advertising associate in Wilson Sonsini Goodrich & Rosati's Palo Alto and San Diego offices. +/-

He assists clients in U.S. and foreign trademark matters, including clearance and selection of trademarks, prosecution of trademark applications and trademark enforcement.

Matt counsels clients concerning brand protection across all consumer touchpoints, ranging from product packaging to online destinations such as social media websites. He represents clients in federal litigation concerning trademark, copyright and advertising issues, in trademark cancellation and opposition proceedings before the Trademark Trial and Appeal Board of the U.S. Patent and Trademark Office and in arbitration proceedings involving Internet domain names.

Matt advises clients in advertising activities, including how to structure and conduct sweepstakes and contests. Matt also represents companies in complex transactions involving intellectual property rights and advertising matters. His clients span numerous industries, including software, hardware, pharmaceuticals, medical devices, financial services, retail services and apparel.

James Huie is a corporate and securities associate in Wilson Sonsini Goodrich & Rosati's Palo Alto office. +/-

James advises companies on general corporate matters, including formation and operation, corporate governance, early- and later-stage venture capital financings, debt financings and public offerings.

He also advises companies on transaction matters and has worked on a number of mergers and acquisition transactions. Additionally, James has experience representing a number of venture capital firms in venture capital financings.

When it comes to understanding the patent landscape in the life sciences, there are very few patent lawyers more experienced than Mika Reiner Mayer. +/-

She has become one of the most sought-after patent lawyers in the medical device, drug delivery, and pharmaceutical fields. In addition to preparing and prosecuting patent applications, she provides strategic patent portfolio analysis for her clients. She works extensively in performing both investor-side and company-side IP due diligence reviews. The potential investments she has overseen range in size from small seed investments to multi-billion-dollar acquisitions in the medical device, drug delivery, and pharmaceutical fields. Ms. Mayer is also often relied upon to assist with some of the firm’s litigation matters involving technologies within her areas of expertise.

Ms. Mayer develops IP strategies and prosecutes patent applications with a laser focus on protecting her clients’ interests and maximizing their value and commercial success. Her prosecution and due diligence engagements have helped her clients shore up their patent portfolios and raise capital to further develop their technologies. She led the IP due diligence for Gilead Sciences’ acquisition of YM Biosciences as well as the IP due diligence for Astellas Pharmaceutical’s $4 billion hostile takeover of OSI Pharmaceuticals. In all, Ms. Mayer has participated in, or led, more than 400 IP due diligence reviews for some of the most sophisticated health care companies and investors in the world.

Ms. Mayer is consistently called upon by top decision makers in the medical device, drug delivery, and pharmaceutical communities for her ability to translate IP risks into business risks, and provide strategic guidance and oversight in this regard. As these industries have gone global, so has her practice, with companies around the world utilizing her expertise.

She is a guest lecturer for Stanford’s Biodesign Innovation Class, a current member of the Science Accelerator Committee of the American Heart Association, and a board member of the Women in Law Empowerment Forum.

Dr. Madhuri (Mani) Roy is an associate in the firm’s Intellectual Property Group in the Palo Alto office. Dr. Roy specializes in patent prosecution and counseling for clients in the areas of biotechnology and pharmaceuticals. +/-

Dr. Roy brings over ten years of integrative biotechnology experience to her practice. She has industry experience in mid-size and large biotech companies in the areas of discovery, target validation, screening and in vivo pharmacology. She has also conducted academic research in the molecular and cellular aspects of neurodegenerative and neuropsychiatric diseases. Dr. Roy is the author of numerous scientific publications.

Prior to law school, Dr. Roy worked as a patent agent at an internationally recognized law firm where her practice focused on patent prosecution and performing due diligence for start-up biotechnology companies.

Dr. Roy holds a J.D. magna cum laude from the Santa Clara University School of Law. During law school, she specialized in intellectual property. She received her Ph.D. in neuroscience from Stanford University where her research focused on the molecular and cellular aspects of gene therapy for the central nervous system, and she holds a B.A. from Cornell University in biochemistry.

Dr. Roy is admitted to practice before the United States Patent & Trademark Office and is a member of the California State Bar.